New Zealand markets open in 7 hours 16 minutes

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
198.24+1.45 (+0.74%)
As of 09:44AM EDT. Market open.

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200

Full-time employees1,665

Key executives

NameTitlePayExercisedYear born
Mr. Michael W. Bonney B.A.Exec. Chairman317.97kN/A1958
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChBCEO & Director1.23M6.7M1963
Dr. Akshay K. Vaishnaw M.D., Ph.D.Pres1.09M2.83M1963
Mr. Jeffrey V. Poulton M.B.A.CFO & Exec. VP914.05kN/A1968
Mr. Tolga Tanguler M.B.A.Exec. VP & Chief Commercial Officer875.86kN/AN/A
Dr. Alfred W. Boyle Ph.D.Chief Technical Operations & Quality OfficerN/AN/AN/A
Dr. Kevin Joseph Fitzgerald Ph.D.Sr. VP, Head of Research & Chief Scientific OfficerN/AN/A1968
Ms. Christine Regan LindenboomSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Indrani M. Lall Franchini J.D.Exec. VP, Chief Legal Officer & Sec.N/AN/A1972
Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Alnylam Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2022 is 4. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.